Inspire Medical Systems, Inc. (INSP) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High gross margin ⢠Margin volatility INSP is cash-rich with low leverage and high gross margins, but heavy SG&A/R&D, a negative retained earnings balance and volatile taxâdriven quarterly gains cloud the sustainability of its operating profits. #cash-richâ #high-op-exâ
Price Behavior
Key Price Behavior Insights: ⢠Lower highs/lows ⢠Elevated volatility ⢠Support base forming Support Level: $58.00â$59.50 Resistance Level: $60.00â$65.00 Over the last month INSP has been in a clear downtrend, dropping sharply from lateâJanuary highs into the 2026â03â13 low, holding near lowâ58s/upperâ50s support with a nearby resistance band in the lowâtoâmidâ$60s that must be reclaimed to turn constructive.
Sentiment & News
Key News Insights: ⢠Product/R&D momentum ⢠Legal investigation ⢠Price volatility Inspire shows R&D-driven product momentum and investor outreach but faces near-term stock weakness and an active legal probe that could pressure valuation.
AI Summary
INSP has shifted from a growth-story to a cashâflow/margin story where the investment hinges on management converting structurally high gross margins into repeatable operating profitsâso investors should watch for consecutive quarters of operatingâmargin expansion, clear evidence of Inspire V implant cadence converting inventory to sales, and resolution or narrowing of securities litigation/reimbursement overhangs as the specific catalysts that will validate upside (and whose failure would meaningfully depress the thesis).
Description
Inspire Medical Systems develops and markets minimally invasive treatments for obstructive sleep apnea in the United States and abroad. Its core product is an implanted hypoglossal nerve neurostimulation system used to treat moderate to severe OSA, and the company is progressing a closed-loop device that monitors respiration and delivers targeted stimulation to keep the airway open. The company was incorporated in 2007 and is based in Golden Valley, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 2 | Dec 9 | INSP | Inspire Medical Systems, Inc. | Compelling short-term momentum with a 75% price surge over 21 days, driven by Q3 earnings beat, raised EPS guidance, growing Inspire V system adoption, positive reimbursement changes for 2026, but tempered by pending securities class-action risks and margin compression. | Closed | +5.0% |